Demonstrated tolerability in patients with PAH^1,2

Adverse events were mild to moderate in severity, and overall, did not result in treatment discontinuation^1,2*

*This was observed in the safety population, which included all patients who received at least 1 dose of Yutrepia.

SAFETY PROFILE FOR YUTREPIA FROM THE INSPIRE TRIAL^1,2

Adverse reactions occurring in >4% if patients at Month 2 in the safety population.¹

Patients were on stable doses of inhaled treprostinil solution for at least 3 months prior to enrollment in the study and transitioned to treatment with YUTREPIA.¹

Patients were prostacyclin naïve and were taking no more than 2 approved oral PAH therapies for at least 3 months at time of enrollment and addition of treatment with YUTREPIA.¹

View data

Adverse events were generally mild to moderate in severity²

Treatment-emergent adverse events reported for ≥10% of patients in the safety population

RTI = respiratory tract infection.

Demonstrated tolerability in patients with PAH^1,2

Adverse events were mild to moderate in severity, and overall, did not result in treatment discontinuation^1,2*

SAFETY PROFILE FOR YUTREPIA FROM THE INSPIRE TRIAL^1,2

Adverse events were generally mild to moderate in severity²

NEXT: How to dose YUTREPIA

INDICATION AND IMPORTANT SAFETY INFORMATION

Demonstrated tolerability in patients with PAH1,2

Adverse events were mild to moderate in severity, and overall, did not result in treatment discontinuation1,2*

SAFETY PROFILE FOR YUTREPIA FROM THE INSPIRE TRIAL1,2

Adverse events were generally mild to moderate in severity2

NEXT: How to dose YUTREPIA

Demonstrated tolerability in patients with PAH^1,2

Adverse events were mild to moderate in severity, and overall, did not result in treatment discontinuation^1,2*

SAFETY PROFILE FOR YUTREPIA FROM THE INSPIRE TRIAL^1,2

Adverse events were generally mild to moderate in severity²